0ZUQuZQ7oqY https://histock.tw/talk/live.aspx?name=gtalk&id=1280 20240612 何毅里長伯

台股 » 個股 » 生華科 » 籌碼相關 » 券商分點績效

生華科

(6492)
可現股當沖
  • 股價
    41.80
  • 漲跌
    ▼0.80
  • 漲幅
    -1.88%
  • 成交量
    182
  • 產業
    上櫃 生技醫療類股
  • 148人加入追蹤

    立即追蹤

  • 本地時間:13:30(已收盤)

     
生華科 (6492)籌碼相關-券商分點績效/獲利分析
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

«前一日     2024/04/23 ~ 2024/04/30     後一日»

券商獲利排行 - 2024/04/23 ~ 2024/04/30

券商分點績效總損益(仟)己實現(仟)未實現(仟)買賣超買張賣張均價均買均賣現價
  2.78%36.2036.23232040.740.7041.8
  1.81%22.3022.33030041.141.1041.8
  2.39%19.5019.52020040.840.8041.8
  1.75%16.4-0.717.21823540.840.840.741.8
  1.28%15.2015.22129841.141.141.141.8
  1.54%14.54.89.711231241.140.941.341.8
  1.50%9.909.91616041.241.2041.8
  1.96%9.609.6121204141041.8
  2.01%9-0.29.21011140.940.940.741.8
  2.62%8.508.588040.740.7041.8
  1.29%6.97.2-0.3-1121341.240.941.541.8
  1.65%6.806.81010041.141.1041.8
  2.73%5.505.555040.740.7041.8
  2.35%4.80.74.145140.940.841.541.8
  2.90%4.704.744040.640.6041.8
  2.29%4.60.14.645140.740.740.741.8
  2.83%4.604.644040.740.7041.8
  0.99%4.504.51111041.441.4041.8
  2.70%4.404.444040.740.7041.8
  2.05%4.204.25504141041.8
  1.63%40.23.836240.940.840.941.8
  2.45%40444040.840.8041.8
  2.34%3.80.8334140.940.841.641.8
  0.71%3.8-0.44.21013341.441.441.341.8
  2.26%3.703.744040.940.9041.8
  1.51%3.7-0.34561414140.741.8
  1.12%3.703.778041.341.341.441.8
  0.58%3.603.61415041.641.641.341.8
  0.77%3.503.51111041.541.5041.8
  1.06%3.13.1007741.140.841.341.8
  2.49%30333040.840.8041.8
  2.41%2.902.933040.840.8041.8
  1.61%2.60.91.724241.140.941.441.8
  2.96%2.402.422040.640.6041.8
  2.96%2.402.422040.640.6041.8
  1.91%2.302.33304141041.8
  2.77%2.202.222040.740.7041.8
  2.70%2.202.212040.740.741.541.8
  2.70%2.202.222040.740.7041.8
  2.70%2.202.222040.740.7041.8
  1.33%2.202.244041.341.3041.8
  2.64%2.102.122040.740.7041.8
  2.58%2.102.122040.840.8041.8
  2.58%2.102.122040.840.8041.8
  2.51%20.91.212140.940.641.541.8
  2.45%20222040.840.8041.8
  2.45%20222040.840.8041.8
  2.39%1.901.922040.840.8041.8
  2.33%1.901.922040.940.9041.8
  2.33%1.901.922040.940.9041.8

券商虧損排行 - 2024/04/23 ~ 2024/04/30

券商分點績效總損益(仟)己實現(仟)未實現(仟)買賣超買張賣張均價均買均賣現價
  -2.04%-41.70-41.7-500504104141.8
  -2.17%-27.50.3-27.8-3013140.940.640.941.8
  -2.70%-23.10-23.1-2102140.7040.741.8
  -2.81%-20.60-20.6-1801840.7040.741.8
  -2.06%-11.80-11.8-140144104141.8
  -2.96%-8.40-8.4-70740.6040.641.8
  -2.58%-8.4-0.7-7.7-71840.841.440.741.8
  -2.05%-8.40-8.4-100104104141.8
  -1.46%-7.80.5-8.3-1211341.140.741.141.8
  -2.70%-7.70-7.7-70740.7040.741.8
  -1.66%-7.50-7.5-1101141.1041.141.8
  -1.95%-7.20-7.2-9094104141.8
  -1.45%-7.10-7.1-1201241.2041.241.8
  -0.79%-5.8-2.7-3.1-3151840.94140.841.8
  -2.75%-5.60-5.6-50540.7040.741.8
  -2.70%-5.50-5.5-50540.7040.741.8
  -0.78%-5.50-5.5-1701741.5041.541.8
  -2.70%-5.50-5.5-50540.7040.741.8
  -1.88%-5.40-5.4-7074104141.8
  -2.83%-4.60-4.6-40440.7040.741.8
  -2.70%-4.40-4.4-40440.7040.741.8
  -2.70%-4.40-4.4-40440.7040.741.8
  -1.95%-40-4-5054104141.8
  -1.62%-40-4-60641.1041.141.8
  -1.56%-3.90-3.9-60641.2041.241.8
  -2.26%-3.70-3.7-40440.9040.941.8
  -0.33%-3.61.9-5.5-5212740.840.840.941.8
  -2.20%-3.60-3.6-40440.9040.941.8
  -1.75%-3.6-1.2-2.4-23540.84140.641.8
  -1.43%-3.50-3.5-42640.940.940.941.8
  -2.11%-3.40-3.4-40440.9040.941.8
  -2.05%-3.3-0.4-2.9-31440.941.340.841.8
  -2.24%-2.70-2.7-20340.94140.941.8
  -2.20%-2.70-2.7-30340.9040.941.8
  -2.96%-2.40-2.4-20240.6040.641.8
  -1.95%-2.40-2.4-3034104141.8
  -1.92%-2.3-0.2-2.2-21340.840.940.741.8
  -2.83%-2.30-2.3-20240.7040.741.8
  -2.75%-2.20-2.2-20240.7040.741.8
  -2.70%-2.20-2.2-20240.7040.741.8
  -2.70%-2.20-2.2-10240.741.540.741.8
  -1.80%-2.20.1-2.3-21340.740.640.741.8
  -2.58%-2.10-2.1-20240.8040.841.8
  -2.58%-2.10-2.1-20240.8040.841.8
  -1.00%-2.10.1-2.2-32541.14141.141.8
  -2.50%-20-2-20240.8040.841.8
  -2.33%-1.90-1.9-20240.9040.941.8
  -2.33%-1.90-1.9-10240.94140.941.8
  -2.33%-1.90-1.9-20240.9040.941.8
  -1.00%-1.70-1.7-40441.4041.441.8
上櫃「肥貓」董監現形 台嘉碩、大宇資、穩懋、生華科為前四肥Anue鉅亨-2024/04/15
生華科治療新冠、流感等泛病毒感染新藥 將啟動二期臨床Anue鉅亨-2023/11/21
生華科泛病毒感染肺炎新藥 向美申請二期臨床Anue鉅亨-2023/10/19
生華科 相關文章
生華科 相關影音